provide expert advice and guidance to the Secretary 
on scientific, technical and other matters of special 
interest to the Department of Health and Human 
Services regarding current and future chemical, bio-
logical, nuclear, and radiological agents, whether nat-
urally occurring, accidental, or deliberate. 
‘‘(2) MEMBERSHIP.—The membership of the 
Board shall be comprised of individuals who represent 
the Nation’s preeminent scientific, public health, and 
medical experts, as follows— 
‘‘(A) such Federal officials as the Secretary 
may determine are necessary to support the 
functions of the Board; 
‘‘(B) four individuals representing the 
pharmaceutical, biotechnology, and device indus-
tries; 
‘‘(C) four individuals representing aca-
demia; and 
‘‘(D) five other members as determined ap-
propriate by the Secretary. 
‘‘(3) TERM OF APPOINTMENT.—A member of the 
Board described in subparagraph (B), (C), or (D) of 
paragraph (2) shall serve for a term of 3 years, except 
that the Secretary may adjust the terms of the initial 
VerDate Aug 31 2005 
04:20 Sep 27, 2006
Jkt 049200
PO 00000
Frm 00017
Fmt 6652
Sfmt 6203
E:\BILLS\H5533.RH
H5533
CCOLEMAN on PROD1PC71 with BILLS
Board appointees in order to provide for a staggered 
term of appointment for all members. 
‘‘(4) CONSECUTIVE
APPOINTMENTS; 
MAXIMUM 
TERMS.—A member may be appointed to serve not 
more than 3 terms on the Board and may serve not 
more than 2 consecutive terms. 
‘‘(5) DUTIES.—The Board shall— 
‘‘(A) advise the Secretary on current and 
future trends, challenges, and opportunities pre-
sented by advances in biological and life sciences, 
biotechnology, and genetic engineering with re-
spect to threats to biodefense or public health se-
curity posed by naturally occurring infectious 
diseases and chemical, biological, radiological, 
and nuclear agents; 
‘‘(B) at the request of the Secretary, review 
and consider any information and findings re-
ceived from the working groups established under 
subsection (b); and 
‘‘(C) at the request of the Secretary, provide 
recommendations and findings for expanded, in-
tensified, and coordinated biodefense research 
and development activities. 
‘‘(6) MEETINGS.— 
VerDate Aug 31 2005 
04:20 Sep 27, 2006
Jkt 049200
PO 00000
Frm 00018
Fmt 6652
Sfmt 6203
E:\BILLS\H5533.RH
H5533
CCOLEMAN on PROD1PC71 with BILLS
‘‘(A) INITIAL MEETING.—Not later than one 
year after the date of enactment of the Biodefense 
and Pandemic Vaccine and Drug Development 
Act of 2006, the Secretary shall hold the first 
meeting of the Board. 
‘‘(B) SUBSEQUENT MEETINGS.—The Board 
shall meet at the call of the Secretary, but in no 
case less than twice annually. 
‘‘(7) VACANCIES.—Any vacancy in the Board 
shall not affect its powers, but shall be filled in the 
same manner as the original appointment. 
‘‘(8) CHAIRPERSON.—The Secretary shall ap-
point a chairperson from among the members of the 
Board. 
‘‘(9) POWERS.— 
‘‘(A) HEARINGS.—The Board may hold 
such hearings, sit and act at such times and 
places, take such testimony, and receive such evi-
dence as the Board considers advisable to carry 
out this subsection. 
‘‘(B) POSTAL SERVICES.—The Board may 
use the United States mails in the same manner 
and under the same conditions as other depart-
ments and agencies of the Federal Government. 
‘‘(10) PERSONNEL.— 
VerDate Aug 31 2005 
04:20 Sep 27, 2006
Jkt 049200
PO 00000
Frm 00019
Fmt 6652
Sfmt 6203
E:\BILLS\H5533.RH
H5533
CCOLEMAN on PROD1PC71 with BILLS
‘‘(A) EMPLOYEES OF THE FEDERAL GOV-
ERNMENT.—A member of the Board that is an 
employee of the Federal Government may not re-
ceive additional pay, allowances, or benefits by 
reason of the member’s service on the Board. 
‘‘(B) OTHER MEMBERS.—A member of the 
Board that is not an employee of the Federal 
Government may be compensated at a rate not 
to exceed the daily equivalent of the annual rate 
of basic pay prescribed for level IV of the Execu-
tive Schedule under section 5315 of title 5, 
United States Code, for each day (including 
travel time) during which the member is engaged 
in the actual performance of duties as a member 
of the Board. 
‘‘(C) TRAVEL EXPENSES.—Each member of 
the Board shall receive travel expenses, including 
per diem in lieu of subsistence, in accordance 
with applicable provisions under subchapter I of 
chapter 57 of title 5, United States Code. 
‘‘(D) DETAIL
OF
GOVERNMENT
EMPLOY-
EES.—Any Federal Government employee may 
be detailed to the Board with the approval for 
the contributing agency without reimbursement, 
VerDate Aug 31 2005 
04:20 Sep 27, 2006
Jkt 049200
PO 00000
Frm 00020
Fmt 6652
Sfmt 6203
E:\BILLS\H5533.RH
H5533
CCOLEMAN on PROD1PC71 with BILLS
and such detail shall be without interruption or 
loss of civil service status or privilege. 
‘‘(b) DEFINITIONS.—Any term that is defined in sec-
tion 319L and that is used in this section shall have the 
same meaning in this section as such term is given in sec-
tion 319L. 
‘‘(c) AUTHORIZATION OF APPROPRIATIONS.—There are 
authorized to be appropriated $1,000,000 to carry out this 
section for each of the fiscal years 2007 and 2008.’’. 
SEC. 4. CLARIFICATION OF COUNTERMEASURES COVERED 
BY PROJECT BIOSHIELD. 
(a) QUALIFIED COUNTERMEASURES.—Section 319F– 
1(a)(2) of the Public Health Service Act (42 U.S.C. 247d– 
6a(a)(2)) is amended— 
(1) by amending subparagraph (A) to read as 
follows: 
‘‘(A) diagnose, mitigate, prevent, or treat 
harm from any biological agent (including orga-
nisms that cause an infectious disease) or toxin, 
or from any chemical, radiological, or nuclear 
agent, that may cause a public health emergency 
affecting national security; or’’; 
(2) in subparagraph (B), by striking ‘‘treat, 
identify, or prevent harm’’ and inserting ‘‘diagnose, 
mitigate, prevent, or treat harm’’; and 
VerDate Aug 31 2005 
04:20 Sep 27, 2006
Jkt 049200
PO 00000
Frm 00021
Fmt 6652
Sfmt 6203
E:\BILLS\H5533.RH
H5533
CCOLEMAN on PROD1PC71 with BILLS